Abstracts Archive - Page 1740 of 2425 - ACR Meeting Abstracts

Abstract Number: 759 • 2015 ACR/ARHP Annual Meeting
Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients
Manuel Ugarte-Gil^1,2, César Sánchez-Zúñiga³, Rocio V. Gamboa-Cardenas¹, Madeley Aliaga-Zamudio³, Francisco Zevallos¹, Giannina Tineo-Pozo³, Jorge M. Cucho-Venegas¹, Ana Mosqueira-Riveros³, Risto Perich-Campos^1,4, Jose Alfaro-Lozano¹, Mariela Medina¹, Zoila Rodriguez-Bellido^1,4, Graciela S. Alarcon⁵ and Cesar A. Pastor-Asurza^1,4, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Molecular Biology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Peripheral CD4+CD28null T-cells are a subset of long-lived cytotoxic CD4+ T-cells with pro-inflammatory functions, and they are increased in autoimmune and cardiovascular diseases. Prolactin…
Abstract Number: 760 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)
Andreas Schwarting¹, Mary Anne Dooley², David Roth³, Lisa Edwards⁴, April Thompson⁴ and Barbara Wilson⁴, ¹ACURA Kliniken, Bad Kreuznach, Germany, ²University of North Carolina, Chapel Hill, NC, ³GlaxoSmithKline, King of Prussia, PA, ⁴GlaxoSmithKline, Chapel Hill, NC
Background/Purpose: Belimumab is licensed as add-on therapy to standard lupus care (SoC) in patients with active SLE. Physicians have inquired about the efficacy and safety…
Abstract Number: 761 • 2015 ACR/ARHP Annual Meeting
Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache
Ji-Min Kim¹, Tae-Han Lee¹, Chang-Nam Son¹, Sung Soo Kim², Hyuk Won Chang³ and Sang-Hyon Kim¹, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ³Department of Radiology, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (SLE) includes a broad spectrum of neurologic and psychiatric manifestations. One of the most commonly observed neuopsychiatric symptoms is headache.…
Abstract Number: 762 • 2015 ACR/ARHP Annual Meeting
The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Arundip Asaduzzaman¹, Babak Noamani², Denisse Bonilla³, Dafna Gladman⁴, Murray Urowitz^5,6, Paul R. Fortin⁷, Carolina Landolt-Marticorena⁸ and Joan E. Wither⁹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸1E420/Div of Rheumatology, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Type I interferon (IFN) is thought to play an important part in the pathophysiology of systemic lupus erythematosus (SLE), and cross-sectional data suggests an…
Abstract Number: 763 • 2015 ACR/ARHP Annual Meeting
Lupus-Related SNPs and Risk of Diffuse Large B-Cell Non-Hodgkin Lymphoma
Sasha Bernatsky^1,2, John Spinelli³, Patrick M. Gaffney⁴, Karin E Smedby⁵, Rosalind Ramsey-Goldman⁶, Sophia Wang⁷ and Ann E. Clarke⁸, ¹Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Centre, McGill University, Montreal, QC, Canada, ³School of Population and Public Health, University of British Columbia, Vancouver, QC, Canada, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁶Fsm # M300, Northwestern University, Chicago, IL, ⁷Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute, Duarte, CA, ⁸Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada
Background/Purpose: The determinants behind the increased risk of non-Hodgkin Lymphoma (NHL) in systemic lupus (SLE) are unclear. The most common type of NHL in SLE…
Abstract Number: 764 • 2015 ACR/ARHP Annual Meeting
Gastrointestinal Adverse Events of Azathioprine in Daily Clinical Practice: Independent of Thiopurine Methyltransferase Activity
Eun Young Ahn¹, Hyun Mi Kwon¹, Sung-Hwan Park², Yeong Wook Song¹ and Kichul Shin³, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, South Korea
Background/Purpose: Azathioprine (AZA) is a commonly used immunosuppressive agent for a number of systemic rheumatic diseases. Although it is regarded to be relatively safe to…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 766 • 2015 ACR/ARHP Annual Meeting
Clinical and Immunological Characteristics of 150 Systemic Lupus Erythematosus Patients in Urban Jamaica
Keisha Maloney¹, Trevor Ferguson² and Karel De Ceulaer³, ¹Department of Medicine,, University of the West Indies, Kingston 7, Jamaica, ²Epidemiology Research Unit, Tropical Medicine Research Institute, University of the West Indies, Kingston 7, Jamaica, ³Internal Medicine, University of the West Indies, Kgn 7, Jamaica
Background/Purpose: Epidemiological studies in systemic lupus erythematosus (SLE) have been reported in the literature in many countries and ethnic groups. Although SLE in Jamaica has…
Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting
Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Stuart L. Silverman¹, Derren Barken², John Conklin³, Claudia Ibarra⁴ and Thierry Dervieux⁵, ¹OMC Clinical Research Center, Beverly Hills, CA, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…
Abstract Number: 768 • 2015 ACR/ARHP Annual Meeting
The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Anca Askanase¹, Teja Kapoor², Cynthia Aranow³, Karen H. Costenbader⁴, Jennifer Grossman⁵, Diane L. Kamen⁶, S. Sam Lim⁷, Mimi Kim⁸, Paola Daly^9,10, Leslie M. Hanrahan¹¹ and Joan T. Merrill¹², ¹NYU School of Medicine, New York, NY, ²Columbia University, New York, NY, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Rheumatology, UCLA, LA, CA, ⁶Medicine, Medical University of South Carolina, Charleston, SC, ⁷Emory University School of Medicine, Atlanta, GA, ⁸Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁹Lupus Foundation of America, Washington DC, DC, ¹⁰Lupus Foundation of America, Washington, DC, ¹¹Lupus Fnd of America, Washington, DC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Current SLE disease activity measures, such as SLEDAI and BILAG, can be challenging to score and interpret, making them impractical for use in…
Abstract Number: 769 • 2015 ACR/ARHP Annual Meeting
Evaluation of Soluble Alpha-Klotho in Neuropsychiatric Systemic Lupus Erythematosus
Kunihiro Ichinose¹, Takeshi Ushigusa², Masataka Umeda¹, Tomohiro Koga², Atsushi Kawakami² and Shuntaro Sato³, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan
Evaluation of Soluble alpha-Klotho in Neuropsychiatric Systemic Lupus ErythematosusABSTRACTBackground/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE that presents a variety of…
Abstract Number: 770 • 2015 ACR/ARHP Annual Meeting
Circulating Levels of iC3b and C3 Correlate with Sledai-2K Responder Index-50 (S2K RI-50) Disease Activity Scores: The Castle (Complement Activation Signatures in Systemic Lupus Erythematosus) Study
Alfred Kim¹, Vibeke Strand², Nancy Mathis¹, Deepali Sen³, Jonathan Miner³, Elizabeth Schramm¹, Robin Bruchas⁴, Nick Staten⁴, Paul Olson⁴, Chad Stiening⁴ and John Atkinson¹, ¹Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, Washington University School of Medicine, Saint Louis, MO, ⁴Kypha, Inc., Saint Louis, MO
Background/Purpose: A major unmet need in SLE is the identification of a biomarker that consistently tracks with disease activity. One current approach is measuring complement…
Abstract Number: 771 • 2015 ACR/ARHP Annual Meeting
Convergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to Sledai-2K
Christopher Collins¹, W. Winn Chatham², Howard Busch³, Norman B. Gaylis⁴, Emily Hautamaki⁵ and Siva Narayanan⁶, ¹MedStar Washington Hospital Center, Washington, DC, ²Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Science & Research Institute, Jupiter, FL, ⁴Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁵Ipsos Healthcare, Washington, DC, ⁶Global Evidence, Value and Access, Ipsos Healthcare, Washington, DC
Background/Purpose: Current validated disease assessment instruments (DAIs) in systemic lupus erythematosus (SLE) such as SLEDAI-2K and BILAG, require disease expertise and/or involve complex scoring systems,…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 773 • 2015 ACR/ARHP Annual Meeting
Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA
Megan L. Krause¹, Michael Ettore², Melissa R. Snyder³, Cynthia S. Crowson⁴ and Kevin G. Moder¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Laboratory Medicine, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: In the setting of a negative ANA, antibodies to extractable nuclear antigens (ENA) should be correspondingly negative, but alternative clinical scenarios occasionally arise. This…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].